Pinned Tweet
A flagship initiative. Looking forward to the next steps!✍️
Konza Technopolis’s disclosure on the BioPharma Life Sciences Park PPP Project, powering research, innovation & jobs for a healthier tomorrow #SiliconSavannah
133
Apifa Biotech appreciates Swedfund International for its support in advancing the development of Kenya’s first Biopharma Life Sciences Park.
This partnership is a strong vote of confidence for this project. It brings us closer to realizing a vision that will not only transform Kenya’s pharmaceutical landscape but also strengthen the region’s manufacturing capacity, advance access to essential medicines and biologics, create opportunities for innovation and investment, and contribute to Africa’s health security and self-reliance. #ApifaBiotech.
Apifa Biotech is establishing a pharmaceutical and life sciences manufacturing hub at #Konza Technopolis to support Kenya's efforts to strengthen #local #medicine #production, reduce reliance on pharmaceutical imports, and expand the country's participation in the regional healthcare manufacturing industry. | KBC TV Kenya. | Apifa Biotech, Chief Executive Officer, Dr Frankline Keter.
#ApifaBiotech #LocalProduction #EAC
Apifa Biotech moves to turn its vision of establishing Kenya’s first #Biopharma Life Sciences Park at Konza Technopolis into reality.
Structured as a public-private partnership (PPP) between Apifa Biotech and the @TechnopolisKE Development Authority, the project received approval in April 2026 to advance to the #development phase, marking a significant step towards establishing a world-class pharmaceutical and life sciences manufacturing hub in Kenya.
Today marks another major milestone, with Swedfund International, Sweden’s development finance institution, coming on board to support project preparation and feasibility studies for the proposed development. This funding commitment provides critical momentum to advance the project, strengthen its investment proposition and lay the groundwork for its next phase.
The project will also benefit from the global expertise of Jones Lang LaSalle (#JLL) and #IQVIA, the consortium selected to undertake the feasibility study, bringing together specialist knowledge in life sciences, infrastructure development, investment advisory and healthcare strategy.
Apifa Biotech remains committed to working alongside its partners to expand local production of essential medicines and active pharmaceutical ingredients (#APIs) across Africa through investment in research and development (R&D), the mobilization, structuring, and provision of financing to support pharmaceutical manufacturing, infrastructure development, and industrial capacity expansion across the continent.
@citizentvkenya @ntvkenya @devex
@HealthPolicyW @sarajerving @NationAfrica
@geraldmacharia, @FranKKeter_ , @apiforafrica | #ApifaBiotech #Biopharma #LifeSciences #Parks
Great possibilities require careful thought, strategic planning, and the right groundwork. Transformation is the product of vision, deliberate action, strong partnerships, and a shared commitment to creating possibilities that deliver lasting impact for generations to come.
Tomorrow, 12th November 2026, at JW Marriott, Nairobi, we step into a defining moment shaped by bold ambition, strategic partnerships, and the promise of a transformative future.
We are counting down the hours to an occasion poised to unlock new frontiers, accelerate innovation, and usher in a powerful new chapter for Kenya, the East African Community (EAC), and the entire African continent.
Watch this space. | @TechnopolisKE X @Swedfund
@ppp_kenya @apiforafrica @geraldmacharia @FranKKeter_ @jpokwiri | @NationAfrica @citizentvkenya @ntvkenya @StandardKenya @devex @HealthPolicyW
#ApifaBiotech #Biopharma #LifeSciencesPark
At the Kenya International Investment Conference 2026, Apifa Biotech was highlighted as a key private-sector partner advancing the Life Sciences Park agenda. @apiforafrica @FranKKeter_ @ppp_kenya @kenyanwalstreet #KIICO2026 @geraldmacharia
kenyanwallstreet.com/kenya-l…
The @ppp_kenya Directorate called for increased private-sector financing to expedite the KSh 28.4 billion Life Sciences project, thereby accelerating implementation, de-risking delivery, and anchoring Kenya’s ambition to become a regional hub for pharmaceutical manufacturing.











